<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01752101</url>
  </required_header>
  <id_info>
    <org_study_id>1013-12</org_study_id>
    <nct_id>NCT01752101</nct_id>
  </id_info>
  <brief_title>Identification of a Plasma Proteomic Signature for Lung Cancer</brief_title>
  <official_title>Identification of a Plasma Proteomic Signature for Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Integrated Diagnostics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Integrated Diagnostics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to identify a panel of plasma and/or serum proteins that&#xD;
      differentiates the absence or presence of lung malignancy in samples obtained from subjects&#xD;
      enrolled in this IRB/EC approved study with pulmonary nodules.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Blood samples are obtained from those patients undergoing procedures to determine if a lung&#xD;
      nodule is benign or cancerous. The data from the study will not be used to guide or influence&#xD;
      the treatment of the patients enrolled in this study. There is no change from the normal&#xD;
      standard of care that patients receive.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence rate of Non-Small Cell Lung Cancer</measure>
    <time_frame>24 months after enrollment</time_frame>
    <description>The incidence rate of non-small cell lung cancer in the study population will be correlated to the predictive value of the Sponsor's blood test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Panel of proteins</measure>
    <time_frame>At the end of the study</time_frame>
    <description>The positive and negative predictive value of the test to differentiate between malignancy and inflammatory diseases such as granulomatous disorders.</description>
  </secondary_outcome>
  <enrollment type="Actual">475</enrollment>
  <condition>Precancerous Conditions</condition>
  <condition>Carcinoma</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients undergoing procedure for histologic diagnosis of lung nodule(s)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age ≥ 40&#xD;
&#xD;
          -  any smoking status, e.g. current, former, or never&#xD;
&#xD;
          -  co-morbid conditions, e.g. COPD&#xD;
&#xD;
          -  Nodule size ≥ 4 mm and ≤ 30 mm (up to Stage 2B eligible), any spiculation or ground&#xD;
             glass opacity&#xD;
&#xD;
          -  Pathology: malignant - adenocarcinoma, squamous, or large cell&#xD;
&#xD;
          -  Pathology: benign - inflammatory (e.g. granulomatous, infectious) or non-inflammatory&#xD;
             (e.g. hamartoma)&#xD;
&#xD;
          -  Clinical stage, Primary tumor: ≤T2 (e.g. 1A, 1B, 2A and 2B)&#xD;
&#xD;
          -  Clinical stage, Regional lymph nodes: N0 or N1 only&#xD;
&#xD;
          -  Clinical stage, Distant metastasis: M0 only&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  prior malignancy within 5 years of lung nodule diagnosis&#xD;
&#xD;
          -  No nodule size available&#xD;
&#xD;
          -  No pathology data available for those with&#xD;
&#xD;
          -  Current diagnosis of non-small cell lung cancer&#xD;
&#xD;
          -  Clinical stage: Primary tumor ≥T3; Regional lymph nodes: ≥N2; 4 Distant metastasis:&#xD;
             ≥M1&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Russell F. Hudnall</last_name>
    <role>Study Director</role>
    <affiliation>Integrated Diagnostics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kaiser Permanente Northern California</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami - Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North East Alabama Regional Medical Center</name>
      <address>
        <city>Anniston</city>
        <state>Georgia</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greater Baltimore Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lahey Hospital &amp; Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geisinger Medical Center</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiopulmonary Research Science and Technology Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intermountain Healthcare</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Group Health Research Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <study_first_submitted>November 30, 2012</study_first_submitted>
  <study_first_submitted_qc>December 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2012</study_first_posted>
  <last_update_submitted>January 7, 2015</last_update_submitted>
  <last_update_submitted_qc>January 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Precancerous Conditions</keyword>
  <keyword>Carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Precancerous Conditions</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

